Ann: 1st patient dosed in Phase 1b recurrent glioblastoma trial, page-41

It is a huge ask. But lets look at it.

If this raise does its job, CHM are funded to have 3 drugs hitting arms in 4 trials. All those trials will have pivot data read outs before the money runs out. All the trials are novel drugs attacking disease with no effective SOC.

Read out from our GBM drug, if replicated, and there is no reason why it wont be, will lead to an accelerated approval trial.

This market cap does not represent where the company is. This helps to greatly derisk the investment. Directors are deferring payments get Focus available funds into progression of pipeline. This is huge for a small drug development bio tech.

Opportunity like this doesn't come around very often. Those that can afford to participate have the potential of many multiples of return, even with the dilution. Those that cant afford to participate, but hold onto there shares still have huge reward potential.

Raising this money is a very important step for the company. But its happening at a very difficult time, market wise.

We have the drugs, we have the people, we just need the cash.

Lets see how we go.